Comparing the performance of six human papillomavirus tests in a screening population

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 908-913

  Cuzick, J ^a   Cadman, L ^a   Mesher, D ^a   Austin, J ^a   Ashdown Barr, L ^a   Ho, L ^a   Terry, G ^a   Liddle, S ^b   Wright, C ^c   Lyons, D ^c   Szarewski, A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Doctors Laboratory   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

biomarkers; cervix; HPV

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; COLPOSCOPY; CYTOLOGY; DYSKARYOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; POPULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CERVIX UTERI; CYTODIAGNOSIS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84875220574     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.22     Document Type: Article

References (24)

1. Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F (2011) Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol 49(4): 1446-1451.
2. Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Tos AG, Girlando S, Palma PD, Pellegrini A, Schiboni ML, Crucitti P, Pierotti P, Vignato A, Ronco G (2005) Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting. Am J Clin Pathol 124(5): 716-721.
3. Castle PE, Stoler MH, Wright Jr TC, Sharma A, Wright TL, Behrens CM (2011) Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12(9): 880-890.
4. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-1101.
5. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP (2008b) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytologyresults from the Hammersmith study. Int J Cancer 122(10): 2294-2300.
6. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ (2008a) Overview of human papillomavirus based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl 10): K29-K41.
7. Dillner J, Rebolj M, Birembaut P, Petry U, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754.
8. Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, Giachetti C (2009) Analytical characterization of the APTIMA HPV assay. J Clin Virol 45(Suppl 1): S39-S47.
9. Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE et al. PaP Cohort Study Group (2012) Comparison of the cobas human papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol 50(1): 61-65.
10. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, Verkuijten M, Meijer CJ, Snijders PJ (2011) Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 49(11): 3983-3985.
11. Joo S, Salva N, Nater T, Dockter J (2010) Preliminary evaluation of the APTIMA HPV 16 18/45 genotype assay for the detection of human papillomavirus types 16, 18 and 45 in liquid Pap specimens. Poster 252 IPV Montreal (poster).
12. LeBar W, Taylor S, Hook EW (2009) Reproducibility of the BD Viper System with XTR Technology (Extracted Mode) with PreservCyt Liquid Based Cytology Medium. Presented at 25th Clinical Virology Symposium: Daytona Beach, FL.
13. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124(3): 516-520.
14. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G, Desai M, Ho L, Terry G, Williams A, Sasieni P, Cuzick J (2010) Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 102(9): 1405-1410.
15. Molden T, Kraus I, Skomedal H, Nordstrom T, Karlsen F (2007) PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 142(1-2): 204-212.
16. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, Ruiz F, Smith JS (2011) Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 129(3): 691-701.
17. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M (2012) Nucleic Acid tests for the detection of alpha human papillomaviruses. Vaccine 30(Suppl 5): F100-F106.
18. Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Vrtacnik Bokal E, Jancar N, Klavs I (2011) Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test and Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 49(5): 1721-1729.
19. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13(1): 78-88.
20. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia R, Zorzi P, ZappaM M, Segnan N, Cuzick J (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249-257.
21. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter WP, Lyons D, Cuzick J (2008) Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 11: 3033-3042.
22. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J (2012) The Predictors 2 Study: comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 Study. J Clin Microbiol 50(6): 1867-1873.
23. Wright Jr TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL (2012) The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 206(1): 46-e1-46.e11.
24. Wu R, Belinson SE, Du H, Na W, Qu X, Wu R, Liu Y, Wang C, Zhou Y, Zhang L, Belinson JL (2010) Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 20(8): 1411-1414.